Thorough discussion of various Circulating Tumor Cells (CTC) Liquid Biopsy Market related topics in this report will definitely help the clients in studying the market in the competitive landscape. Circulating Tumor Cells (CTC) Liquid Biopsy Market is the most precise, distinctive, realistic and impressive market research report delivered with absolute devotion and understanding of business needs. The data and information collected through research to produce this report is usually quite large and also in complex form. The widespread Circulating Tumor Cells (CTC) Liquid Biopsy Market Report has been prepared by a multilingual research team who are experts in various languages which can be used to conduct international market research efficiently.
Circulating Tumor Cells (CTC) Liquid Biopsy s The market research report involves key parameters namely market analysis, market definition, market segmentation, key market developments, competitive analysis, and research methodology. This market report proves to be an excellent resource providing current and upcoming technical and financial details of the industry up to 2030. Verified and advanced tools like SWOT analysis and Porter's Five Forces Analysis are used carefully while compiling this market research report. By understanding the need to follow certain steps to collect, record and analyze market data, the Circulating Tumor Cells (CTC) Liquid Biopsy s Market report has been prepared.
Data Bridge Market Research analyses that the circulating tumor cells (CTC) liquid biopsy market which was USD 1,173.84 million in 2022, is expected to reach USD 4,170.06 million by 2030, growing at a CAGR of 17.17% during the forecast period of 2023 to 2030.
Explore Further Details about This Research Circulating Tumor Cells (CTC) Liquid Biopsy Market Report https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market
Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope and Segmentation
REPORT METRIC | DETAILS |
Forecast Period | 2023 to 2030 |
Base Year | 2022 |
Historic Years | 2021 (Customizable to 2015-2020) |
Quantitative Units | Revenue in USD Million, Volumes in Units, Pricing in USD |
Segments Covered | Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In Vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection Immunocytochemical Technologies), Application (Cancer Application, Non-Cancer Applications, Non-Invasive Prenatal Testing (NIPT), Organ Transplantation, Infectious Disease Testing), Clinical Application (Early Cancer Screening, Diagnosis, Therapy Selection, Treatment Monitoring, Prognosis and Recurrence Monitoring), Sample Type, (Blood, Urine, Saliva, Cerebrospinal Fluid, Others), Product (Kits Reagents, Blood Collection Tubes, Devices or System), Specimen (Blood, Bone Marrow, Other Body Fluids), End User (Research Academic Institutes, Reference Laboratories Hospitals Physician Laboratories) |
Countries Covered | U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
Market Players Covered | QIAGEN (Germany), Bio-Techne (U.S.), Precision Medical Group, LLC. (U.S.), Aviva Systems Biological Corporation (U.S.), Biocept, Inc. (U.S.), Fluxion Biosciences, Inc. (U.S.), Greiner Bio-One International GmbH (Austria) , Ikonisys (U.S.), Miltenyi Biotec (Germany), IVDiagnostics (U.S.), BioFluidica (U.S.), Canopus Medical (Sweden), Biolidics Limited (Singapore), Creativ MicroTech, Inc. (U.S.), LungLife AI, Inc. (U.S.), Epic Sciences (U.S.), Rarecells Diagnostics (France), ScreenCell (France), Menarini Silicon Biosystems (U.S.). |
Market Opportunities |
|
Market Definition
The liquid biopsy is a type of non-invasive blood test which identifies circulating tumor cells and tumor DNA fragments which are released in the blood by primary tumors and metastatic sites. It is an alternative to surgical biopsy procedure, and it allows surgeon to detect cancer at a very early stage. The circulating tumor cells function as a seed of metastases. The patients who have developed solid tumors it is found in them. The detection and quantification of tumor cells in the blood of cancer patients is allowed by the testing of circulating tumor cells. There are various types of biological phenotypes of circulating tumor cells (CTCs) such as stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity and due to which, a phase of isolation-enrichment is required in their detection.
Global Circulating Tumor Cells (CTC) Liquid Biopsy Dynamics
Drivers
- Rising prevalence of cancer
The rising prevalence of different types of cancer is boosting the market’s growth. The increasing number of cancer cases across the world is fuelling the demand of liquid biopsy. Breast cancer was the most common cancer 2020 with 2.26 million cases and further lung cancer with 2.21 million cases. The rising prevalence of cancer can be reduced through early detection of cancer and appropriate treatment. Circulating cancer cells are suitable for developing preclinical models, particularly 3D organoid cultures, for use in drug screening, disease modelling, genome editing, and organoid biobanks, thus significantly driving the market’s growth.
- Awareness initiatives by global health organizations and government
The governments in various countries and global health organizations are spreading awareness about cancer and other growing diseases. National Cancer Control program of WHO, is a public health program aiming to reduce the growing number of cancer deaths and improve the life of cancer patients. Furthermore, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), initiated by the US Centers for Diseases and Prevention (CDC) in 1991, provides breast cancer screening and diagnosis for uninsured and low-income patients in the US every year. The rising awareness in people about the effects and necessity to cure the diseases is increasing the liquid biopsy tests and treatments further driving the market’s growth.
Key Offerings:
- Past Market Size and Competitive Landscape (2018 to 2022)
- Past Pricing and price curve by region (2018 to 2022)
- Market Size, Share, Size Forecast by different segment | 2023−2029
- Market Dynamics – Growth Drivers, Restraints, Opportunities, and Key Trends by Region
- Circulating Tumor Cells (CTC) Liquid Biopsy Market Segmentation – A detailed analysis by segment with their sub-segments and Region
- Competitive Landscape – Profiles of selected key players by region from a strategic perspective
- Competitive landscape – Market Leaders, Market Followers, Regional player
- Competitive benchmarking of key players by region
- PESTLE Analysis
- PORTER’s analysis
- Value chain and supply chain analysis
- Legal Aspects of Business by Region
- Lucrative business opportunities with SWOT analysis
- Recommendations
Browse Related Reports:
Hand Sanitizer Market Size And Share Analysis Report,
Hard Candy Market by Size, Share, Forecast, Trends
Fluid Catalytic Cracking (FCC) Market Size Report- Industry Growth Analysis
micromachining market Size, Industry Share Forecast
low power wide area network market Size, Share, Growth | Opportunities,
Cognitive SEcurity Market Size, Share Analysis Report
Digitally Printed Wallpaper Market Size, Share, Growth Analysis
About Data Bridge Market Research:
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com
